5AM Ventures Managing Partner Scott Rocklage

Dr. Scott. M. Rocklage joined 5AM Ventures in 2003 as a venture partner then became a managing partner in 2004. Dr. Rocklage served as the acting chief executive officer of EPIRUS Biopharmaceuticals, Inc since May 6, 2016, to May 11, 2016, and then as its chief executive officer since May 11, 2016, to July 25, 2016. He was the president and chief executive officer of Amersham Health. He served as the co-president and executive chairman when he was at Llypsa, Inc. From July 1994 to March 2001 he acted as the president of Cubist Pharmaceuticals, Inc. He was also the founding chief executive officer of the same company (July 1994 to June 2003).


He served as the chief executive officer and president of Nycomed Salutar, Inc from 1990 to 1994. Dr. Rocklage was the chairman, president, and chief executive officer of Nycomed Interventional, Inc from 1992 to 1994. From 2013, he has served as the chairman of the board at Citadara Therapeutics. He has been the chairman of Novira Therapeutics since August 2012. He serves on the board of associates at Whitehead Institute and as chair of the board at Rennovia, Inc. He has served as the director of Pulmatrx since March 2006. He was the executive chairman of Miikana Therapeutics, Inc and Semprus. He served as the director of EPIRUS Biopharmaceuticals since July 2014 to July 2016.


Dr. Scott Rocklage was the chairman of the board of Semprus BioSciences Corp and is currently the director at MDS Proteomics. He served as the director of Relypsa, Inc from August 2007 to June 2014. He was the executive chairman of Relypsa, Inc till June 2014. He was the Director of Achaogen from August 2004 to March 2015.Dr. Rocklage has a scientific background, more than two decades experience in the healthcare management sector and excellent leadership skills. He has made more than a hundred peer-reviewed publications and has been involved in more than thirty U.S patents. He earned a B.S in chemistry from the University of California, Berkeley. He then received his Ph.D. in chemistry from the Massachusetts Institute of Technology (MIT), where he conducted his research in Nobel Peace Prize Winner Richard Shrock’s laboratory.